Biopharma & Life Sciences
Immunocore Holdings Executive Compensation (FY25)
IMCR · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025 ◇ Bahija Jallal | Latest say-on-pay support = May 27, 2026 | Chief executive pay ratio ◇ To the median employee |
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
The paid brief on Immunocore Holdings
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$500 for the Executive Compensation Report. Both reports for $900.
Data as of November 5, 2026Latest filing (8-K): May 27, 2026
6 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
184 figures on this page: 181 cited to the filing that reported them, 3 calculated from figures it prints. See the citations
More on Immunocore Holdings
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Bahija Jallal: $12,852,234 → $10,885,268 (15.3% lower)
CEO pay ratio: 119:1 → 92:1 (22.7% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Immunocore Holdings' chief executive and what were they paid?
Bahija Jallal was paid $10,885,268 in total compensation as Chief Executive Officer for fiscal 2025. Jallal's total was 15.3% lower than the $12,852,234 reported for fiscal 2024.
What was Immunocore Holdings' say-on-pay result?
For fiscal 2025, the say-on-pay proposal drew 77.5% support at the meeting held May 27, 2026.
Which companies are in Immunocore Holdings' peer group?
Companies named in the disclosed peer group include Amicus Therapeutics, Apellis Pharmaceuticals, Arcus Biosciences, Arrowhead Pharmaceuticals and Arvinas, among others.
What is Immunocore Holdings' chief executive pay ratio?
The company reported a chief executive pay ratio of 92:1 for fiscal 2025, against median employee compensation of $117,720.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Bahija Jallal Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Bahija Jallal Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
David Berman Executive Vice President, Head of Research & Development | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Brian Di Donato Former Chief Financial Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Tina St. Leger Chief Human Resources Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Bahija Jallal Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
David Berman Executive Vice President, Head of Research & Development | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Brian Di Donato Former Chief Financial Officer Departed during or after this year | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Tina St. Leger Chief Human Resources Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Bahija Jallal Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Travis Coy Chief Financial Officer and Head of Corporate Development | ◇ | ◇ | — | ◇ | ◇ | — | ◇ | ◇ |
David Berman Former Executive Vice President, Head of Research & Development Departed during or after this year | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Tina St. Leger Chief Human Resources Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | — not reconciled |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Bahija Jallal | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Bahija Jallal | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| David Berman | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| David Berman | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Tina St. Leger | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Tina St. Leger | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Travis Coy | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Bahija Jallal | Option | ◇ | — | ◇ | February 16, 2035 |
| Option | ◇ | — | ◇ | February 15, 2034 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | February 15, 2033 | |
| Option | ◇ | — | ◇ | February 15, 2032 | |
| Travis Coy | Option | ◇ | — | ◇ | December 31, 2034 |
| David Berman | Option | ◇ | — | ◇ | February 16, 2035 |
| Option | ◇ | — | ◇ | February 15, 2034 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | February 15, 2033 | |
| Option | ◇ | — | ◇ | February 15, 2032 | |
| Tina St. Leger | Option | ◇ | — | ◇ | February 16, 2035 |
| Option | ◇ | — | ◇ | March 31, 2032 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | February 15, 2034 | |
| Option | ◇ | — | ◇ | February 15, 2033 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Bahija Jallal
Chief Executive Officer · Employment agreement
| Severance multiple | ◇ |
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
Travis Coy
Chief Financial Officer and Head of Corporate Development · Employment agreement
| Severance multiple | ◇ |
| Severance base | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
William Pao | ◇ | — | ◇ | — | — | — | ◇ |
Professor Sir John Bell Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Siddharth Kaul | ◇ | — | ◇ | — | — | — | ◇ |
Kristine Peterson | ◇ | — | ◇ | — | — | ◇ | ◇ |
Roy S. Herbst | ◇ | — | ◇ | — | — | ◇ | ◇ |
Professor Sir Peter Ratcliffe | ◇ | — | ◇ | — | — | — | ◇ |
Ranjeev Krishana | ◇ | — | ◇ | — | — | — | ◇ |
Bahija Jallal | ◇ | ◇ | — | ◇ | ◇ | ◇ | ◇ |
Robert Perez served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Amicus Therapeutics FOLD
- Apellis Pharmaceuticals APLS
- Arcus Biosciences RCUS
- Arrowhead Pharmaceuticals ARWR
- Arvinas ARVN
- Axsome Therapeutics AXSM
- Beam Therapeutics BEAM
- Bicycle Therapeutics BCYC
- Galapagos NV GLPG
- IDEAYA Biosciences IDYA
- Immatics IMTX
- Intra-Cellular Therapies ITCI
- Ionis Pharmaceuticals IONS
- Mirium Pharmaceuticals MIRM
- TG Therapeutics TGTX
- Xencor XNCR
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | May 27, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | May 15, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | May 23, 2024 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Bahija Jallal (Chief Executive Officer), FY2025 total compensation $10,885,268 (base salary $765,000) [exec_comp, SEC accession 0001140361-26-015122, filed 2026-04-16]What this page does not include
Everything above is a fact Immunocore Holdings disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Immunocore Holdings sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
184 figures on this page: 181 cited to the filing that reported them, 3 calculated from figures it prints.
181 cited to the filing
3 calculated from the filing
Documents cited
- 0001140361-26-022984
- 0001140361-26-015122CEO PAY RATIO · Grants of Plan-Based Awards · Potential Payments Upon Termination
- 0001140361-25-019282
- 0001140361-25-012123
- 0001140361-24-027312
- 0001140361-24-019623
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Immunocore Holdings executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/IMCR (accessed 2026).
Short form: data: Velarion
The paid brief for Immunocore Holdings
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$500 for the Executive Compensation Report. Both reports for $900.
6 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Immunocore Holdings and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Immunocore Holdings discloses
The companies named in IMCR's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}